Krebs Biochemicals publishes Q4 & FY26 Audited Financial Results
Krebs Biochemicals & Industries Limited reported audited financial results for Q4 FY26. The company posted a net loss of ₹233.96 Lakhs for the quarter and ₹2,693.93 Lakhs for the full year. Total income from operations for Q4 FY26 was ₹881.27 Lakhs.
While the company has reported losses, the announcement is a routine disclosure of financial results. The impact is medium as it provides crucial financial health information to investors.
The company reported significant losses for both the quarter and the full financial year, indicating a negative financial performance.
Krebs Biochemicals and Industries Limited has announced its audited financial results for the fourth quarter and the financial year ended March 31, 2026. These results were approved by the Board of Directors in a meeting held on May 21, 2026.
The company has published these results in the newspapers Business Standard (English) and Prajasakti (Telugu) on May 22, 2026. The detailed financial highlights indicate a net loss for the quarter and the full financial year. For the quarter ended March 31, 2026, the company reported a net profit/(loss) after tax of ₹(233.96) Lakhs, compared to ₹(312.65) Lakhs in the same period of the previous year. The total income from operations for the quarter was ₹881.27 Lakhs, an increase from ₹727.85 Lakhs in the prior year quarter.
For the full financial year ended March 31, 2026, the company reported a net profit/(loss) after tax of ₹(2,693.93) Lakhs, a significant increase in loss compared to ₹(1,693.31) Lakhs in the previous financial year. The total income from operations for the full year stood at ₹4,402.08 Lakhs, an increase from ₹2,575.79 Lakhs in the previous year. The basic and diluted Earnings Per Share (EPS) for the year ended March 31, 2026, was ₹(12.49).
What to do with a filing like this
Krebs Biochemicals and Industries Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krebs Biochemicals and Industries Limited. Read the original for the full detail.